{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:57:59Z","timestamp":1792803479665,"version":"4.5.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jare.2025.10.026","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:37:22Z","timestamp":1761187042000},"page":"837-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine"],"prefix":"10.1016","volume":"85","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-4459","authenticated-orcid":false,"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longdan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jare.2025.10.026_b0005","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1111\/bph.13966","article-title":"Melatonin: does it have utility in the treatment of haematological neoplasms?","volume":"175","author":"Li","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10495-016-1244-3","article-title":"Clinical and pathological significance of N-Myc downstream-regulated gene 2 (NDRG2) in diverse human cancers","volume":"21","author":"Hu","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.jare.2025.10.026_b0015","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5192271","article-title":"The Synergistic reducing Drug Resistance effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy","volume":"2021","author":"Tang","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jare.2025.10.026_b0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.semcancer.2022.11.006","article-title":"The role of stem cells in small-cell lung cancer: evidence from chemoresistance to immunotherapy","volume":"87","author":"Guo","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.10.026_b0030","doi-asserted-by":"crossref","unstructured":"Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A. Pathology and Genetics: Tumours of the Urinary System and Male Genital System: Clinical Implications of the 4th Edition of the WHO Classification and Beyond. Eur Urol. 2016;70(1):120-3.","DOI":"10.1016\/j.eururo.2016.03.011"},{"key":"10.1016\/j.jare.2025.10.026_b0035","article-title":"The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0040","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol"},{"issue":"9669","key":"10.1016\/j.jare.2025.10.026_b0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.urolonc.2021.04.013","article-title":"Papillary renal cell carcinoma: Review","volume":"39","author":"Mendhiratta","year":"2021","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2025.10.026_b0060","doi-asserted-by":"crossref","unstructured":"Dobruch J, Oszczud\u0142owski M. Bladder Cancer: Current Challenges and Future Directions. Medicina (Kaunas). 2021;57(8).","DOI":"10.3390\/medicina57080749"},{"issue":"10","key":"10.1016\/j.jare.2025.10.026_b0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.medcli.2017.06.009","article-title":"Bladder cancer: present and future","volume":"149","author":"Martinez Rodriguez","year":"2017","journal-title":"Med Clin (Barc)"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11934-018-0860-6","article-title":"Bladder Cancer Survivorship","volume":"19","author":"Bhanvadia","year":"2018","journal-title":"Curr Urol Rep"},{"issue":"7679","key":"10.1016\/j.jare.2025.10.026_b0075","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/551S33a","article-title":"Bladder cancer","volume":"551","author":"Grayson","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NPR.0000512251.61454.5c","article-title":"Bladder cancer: risk factors, diagnosis, and management","volume":"42","author":"Farling","year":"2017","journal-title":"Nurse Pract"},{"issue":"10","key":"10.1016\/j.jare.2025.10.026_b0085","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2025.10.026_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114203","article-title":"Hereditary spastic paraplegia: Genetic heterogeneity and common pathways","volume":"357","author":"Panza","year":"2022","journal-title":"Exp Neurol"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00391-2017","article-title":"What is precision medicine?","volume":"50","author":"K\u00f6nig","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1377\/hlthaff.2018.0520","article-title":"Precision Medicine","volume":"37","author":"Weil","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110055","article-title":"A renal cell carcinoma tumorgraft platform to advance precision medicine","volume":"37","author":"Elias","year":"2021","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.jare.2025.10.026_b0115","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.scib.2024.03.055","article-title":"Excitatory amino acid transporter supports inflammatory macrophage responses","volume":"69","author":"Gan","year":"2024","journal-title":"Sci Bull (Beijing)"},{"issue":"10","key":"10.1016\/j.jare.2025.10.026_b0120","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1021\/acs.molpharmaceut.2c00034","article-title":"Molecular Imaging of Renal Cell Carcinoma in Precision Medicine","volume":"19","author":"Wu","year":"2022","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0125","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.hoc.2021.02.008","article-title":"Developing Precision Medicine for Bladder Cancer","volume":"35","author":"Guercio","year":"2021","journal-title":"Hematol Oncol Clin N Am"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.urolonc.2024.02.004","article-title":"Precision medicine for prostate cancer: an international perspective","volume":"42","author":"Hamid","year":"2024","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-024-01532-x","article-title":"Decoding the glycoproteome: a new frontier for biomarker discovery in cancer","volume":"17","author":"He","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0140","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-025-58569-w","article-title":"Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies","volume":"16","author":"Ou","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0145","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","article-title":"Genomic profiling in renal cell carcinoma","volume":"16","author":"Dizman","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jare.2025.10.026_b0150","article-title":"Precision Medicine: an Optimal Approach to Patient Care in Renal Cell Carcinoma","volume":"9","author":"Sharma","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7620","key":"10.1016\/j.jare.2025.10.026_b0155","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1038\/537S97a","article-title":"Kidney cancer","volume":"537","author":"Owens","year":"2016","journal-title":"Nature"},{"issue":"17\u201318","key":"10.1016\/j.jare.2025.10.026_b0160","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.jare.2025.10.026_b0165","article-title":"Bladder cancer","volume":"29(2):xiii-xiv","author":"Bellmunt","year":"2015","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s42003-023-04561-3","article-title":"FLI1 and FRA1 transcription factors drive the transcriptional regulatory networks characterizing muscle invasive bladder cancer","volume":"6","author":"Guneri-Sozeri","year":"2023","journal-title":"Commun Biol"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOU.0000000000000601","article-title":"Trimodality therapy for bladder cancer: modern management and future directions","volume":"29","author":"Pham","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-020-01300-8","article-title":"Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer","volume":"20","author":"Yang","year":"2021","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cll.2023.08.010","article-title":"Molecular Pathology of Urothelial Carcinoma","volume":"44","author":"Al-Ahmadie","year":"2024","journal-title":"Clin Lab Med"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0190","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.hoc.2023.04.019","article-title":"Renal Cell Carcinoma of Variant Histology: Biology and Therapies","volume":"37","author":"Msaouel","year":"2023","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00001622-200405000-00010","article-title":"Renal cell carcinoma","volume":"16","author":"Rathmell","year":"2004","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/19336950.2022.2058733","article-title":"Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma","volume":"16","author":"Gong","year":"2022","journal-title":"Channels (Austin)"},{"issue":"7","key":"10.1016\/j.jare.2025.10.026_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071689","article-title":"Atypical Response patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2025.10.026_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-95693-0_1","article-title":"Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment strategies","volume":"1095","author":"Schatten","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","article-title":"Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance","volume":"6","author":"Ge","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006581","article-title":"Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment","volume":"11","author":"Xu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2025.10.026_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112054","article-title":"Mitochondria-targeted high-load sound-sensitive micelles for sonodynamic therapy to treat triple-negative breast cancer and inhibit metastasis","volume":"124","author":"Han","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13402-012-0082-8","article-title":"Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines","volume":"35","author":"Koch","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"issue":"29","key":"10.1016\/j.jare.2025.10.026_b0235","doi-asserted-by":"crossref","first-page":"45225","DOI":"10.18632\/oncotarget.9904","article-title":"Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/modpathol.2009.28","article-title":"FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations","volume":"22","author":"Lott","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jare.2025.10.026_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0250","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"},{"issue":"24","key":"10.1016\/j.jare.2025.10.026_b0255","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","article-title":"FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages that Suppress T-cell Recruitment and Activation","volume":"83","author":"Ouyang","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jare.2025.10.026_b0260","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mc.22125","article-title":"PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors","volume":"54","author":"Due\u00f1as","year":"2015","journal-title":"Mol Carcinog"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0265","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00345-020-03213-z","article-title":"VEGF inhibition in urothelial cancer: the past, present and future","volume":"39","author":"Ghafouri","year":"2021","journal-title":"World J Urol"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0270","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.prp.2009.07.015","article-title":"Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas","volume":"205","author":"Donmez","year":"2009","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1758834016667179","article-title":"Incorporating VEGF-targeted therapy in advanced urothelial cancer","volume":"9","author":"Narayanan","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jare.2025.10.026_b0280","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12935-018-0661-5","article-title":"Somatic mutations in renal cell carcinomas from chinese patients revealed by whole exome sequencing","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0285","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer patients in Clinical Trials: a Collaborative Systematic Review and Meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0290","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3346\/jkms.2006.21.4.672","article-title":"MET expression in sporadic renal cell carcinomas","volume":"21","author":"Choi","year":"2006","journal-title":"J Korean Med Sci"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0295","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1158\/1078-0432.CCR-14-2685","article-title":"The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models","volume":"21","author":"Schuller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122653","article-title":"Androgen Receptor Signaling Pathway in Prostate Cancer: from Genetics to Clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"2\u20133","key":"10.1016\/j.jare.2025.10.026_b0305","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10555-013-9474-0","article-title":"Androgen receptor signaling in prostate cancer","volume":"33","author":"Culig","year":"2014","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050898","article-title":"Androgen Receptor-Mediated Transcription in Prostate Cancer","volume":"11","author":"\u00d6zturan","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0315","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1038\/s41467-025-60654-z","article-title":"Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer","volume":"16","author":"Mizuno","year":"2025","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.jare.2025.10.026_b0320","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1158\/1055-9965.EPI-14-0020","article-title":"Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer","volume":"23","author":"Yoo","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0325","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12672-016-0279-9","article-title":"Micro-RNA-204 Participates in TMPRSS2\/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer","volume":"8","author":"Todorova","year":"2017","journal-title":"Horm Cancer"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0330","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/0008-5472.CAN-13-2485","article-title":"p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis","volume":"74","author":"Zhong","year":"2014","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.jare.2025.10.026_b0335","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-23-1439","article-title":"SPOP Mutations Target STING1 Signaling in Prostate Cancer and create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth suppression","volume":"29","author":"Geng","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0340","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41418-021-00913-w","article-title":"SPOP mutations promote p62\/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer","volume":"29","author":"Shi","year":"2022","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0345","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","article-title":"Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations","volume":"20","author":"Rajwa","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jare.2025.10.026_b0350","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-031-27156-4_10","article-title":"Targeted Therapy and Personalized Medicine","volume":"185","author":"Saeed","year":"2023","journal-title":"Cancer Treat Res"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0355","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.7150\/jca.63509","article-title":"Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort","volume":"13","author":"Zsch\u00e4bitz","year":"2022","journal-title":"J Cancer"},{"issue":"3","key":"10.1016\/j.jare.2025.10.026_b0360","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000494359","article-title":"Human Epidermal Growth factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: issues in AssessmentMethods and its Role as Prognostic\/Predictive Marker and Putative Therapeutic Target: a Comprehensive Review","volume":"102","author":"Sanguedolce","year":"2019","journal-title":"Urol Int"},{"issue":"924","key":"10.1016\/j.jare.2025.10.026_b0365","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/pmj.78.924.584","article-title":"Epidermal growth factor receptor and bladder cancer","volume":"78","author":"Colquhoun","year":"2002","journal-title":"Postgrad Med J"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0370","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.21873\/anticanres.15165","article-title":"Epidermal Growth factor based Targeted Toxin for the Treatment of Bladder Cancer","volume":"41","author":"Masilamani","year":"2021","journal-title":"Anticancer Res"},{"issue":"25","key":"10.1016\/j.jare.2025.10.026_b0375","first-page":"00040","article-title":"Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment","volume":"S2090\u20131232","author":"Cui","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.jare.2025.10.026_b0380","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol Res"},{"issue":"23","key":"10.1016\/j.jare.2025.10.026_b0385","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.32361","article-title":"Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma","volume":"125","author":"Mantia","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0390","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.18632\/oncotarget.14263","article-title":"Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: evidence from eight case-control studies","volume":"8","author":"Gong","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0395","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.hoc.2011.04.006","article-title":"Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma","volume":"25","author":"Albiges","year":"2011","journal-title":"Hematol Oncol Clin N Am"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0400","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CAD.0b013e328360335f","article-title":"Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone","volume":"24","author":"Vrdoljak","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jare.2025.10.026_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113431","article-title":"Recent advances in sensor-integrated brain-on-a-chip devices for real-time brain monitoring","volume":"229","author":"Zhao","year":"2023","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0410","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen Signaling in Prostate Cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0415","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094786","article-title":"Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer","volume":"23","author":"Saxby","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0420","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: a Systematic Review and Meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"issue":"20","key":"10.1016\/j.jare.2025.10.026_b0425","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease volume and Risk Subgroups in the phase III ARASENS Trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2025.10.026_b0430","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.2147\/IJN.S434950","article-title":"Dual-Targeted Zeolitic Imidazolate Frameworks Drug delivery System reversing Cisplatin Resistance to Treat Resistant Ovarian Cancer","volume":"19","author":"Xing","year":"2024","journal-title":"Int J Nanomed"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0435","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/curroncol28050289","article-title":"Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in men with Advanced Prostate Cancer","volume":"28","author":"Gheorghe","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0440","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer patients: a Systematic Review and Network Meta-analysis","volume":"9","author":"Mandel","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.jare.2025.10.026_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120031","article-title":"EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways","volume":"286","author":"Rajput","year":"2021","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0450","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00018-022-04320-3","article-title":"FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation","volume":"79","author":"Zhou","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jare.2025.10.026_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111185","article-title":"EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells","volume":"194","author":"Eloy","year":"2020","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0460","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/s41416-020-01052-8","article-title":"EGFR as a stable marker of prostate cancer dissemination to bones","volume":"123","author":"Nasta\u0142y","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0465","article-title":"CMTM5 inhibits the development of prostate cancer via the EGFR\/PI3K\/AKT signaling pathway","volume":"25","author":"Li","year":"2022","journal-title":"Mol Med Rep"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0470","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0475","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004569","article-title":"NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer","volume":"10","author":"Yan","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0480","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: a PD-L1-Blocking Antibody for Bladder Cancer","volume":"23","author":"Inman","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.jare.2025.10.026_b0485","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant Pembrolizumab and Radical Cystectomy in patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year median Follow-up Update of PURE-01 Trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0490","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clgc.2014.03.002","article-title":"Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity","volume":"12","author":"Bellmunt","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0495","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12894-020-00647-w","article-title":"Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations","volume":"20","author":"Ged","year":"2020","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0500","first-page":"92","article-title":"Prognostic factors in patients treated with VEGF-targeted therapies","volume":"8","author":"Choueiri","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17512433.2020.1702025","article-title":"Erdafitinib for the treatment of metastatic bladder cancer","volume":"13","author":"Montazeri","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jare.2025.10.026_b0510","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/ajhp\/zxz329","article-title":"Erdafitinib: a novel therapy for FGFR-mutated urothelial cancer","volume":"77","author":"Roubal","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0515","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ajhp\/zxab464","article-title":"The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer","volume":"79","author":"Hanna","year":"2022","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0520","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0525","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","article-title":"A Molecular Inquiry into the Role of Antibody-Drug Conjugates in bacillus Calmette-Gu\u00e9rin-exposed Non-muscle-invasive Bladder Cancer","volume":"81","author":"Choi","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.jare.2025.10.026_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-Head Comparison of the Expression differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and its Histologic Variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2025.10.026_b0535","article-title":"Ultra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery","volume":"9","author":"Yu","year":"2025","journal-title":"International Journal of Pharmaceutics: X"},{"key":"10.1016\/j.jare.2025.10.026_b0540","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0545","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0550","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"Wenzel","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"10.1016\/j.jare.2025.10.026_b0555","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0560","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/17425255.2022.2122812","article-title":"Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions","volume":"18","author":"Conde-Est\u00e9vez","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"15","key":"10.1016\/j.jare.2025.10.026_b0565","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025180","article-title":"Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: a systematic review and network meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"143","key":"10.1016\/j.jare.2025.10.026_b0570","first-page":"155","article-title":"The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer","volume":"26","author":"Chen","year":"2018","journal-title":"Discov Med"},{"key":"10.1016\/j.jare.2025.10.026_b0575","article-title":"Functional Dendrimer Nanogels for DNA delivery and Gene Therapy of Tumors","author":"Li","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jare.2025.10.026_b0580","article-title":"Deciphering molecular pathways in urological cancers: a gateway to precision therapeutics","author":"Hushmandi","year":"2025","journal-title":"J Adv Res"},{"issue":"25","key":"10.1016\/j.jare.2025.10.026_b0585","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6512","key":"10.1016\/j.jare.2025.10.026_b0590","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.aba7300","article-title":"Macroscopic somatic clonal expansion in morphologically normal human urothelium","volume":"370","author":"Li","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jare.2025.10.026_b0595","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0600","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2017.11","article-title":"The evolving genomic landscape of urothelial carcinoma","volume":"14","author":"Glaser","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0605","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1158\/2159-8290.CD-20-1559","article-title":"Tracking Cancer Evolution through the Disease Course","volume":"11","author":"Bailey","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2025.10.026_b0610","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcdb.2014.08.003","article-title":"Kidney stem cells in development, regeneration and cancer","volume":"36","author":"Dziedzic","year":"2014","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0615","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/cam4.3739","article-title":"Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0620","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.3892\/mmr.2017.7281","article-title":"Significance of the TMPRSS2:ERG gene fusion in prostate cancer","volume":"16","author":"Wang","year":"2017","journal-title":"Mol Med Rep"},{"issue":"12","key":"10.1016\/j.jare.2025.10.026_b0625","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwx235","article-title":"TMPRSS2:ERG Gene Fusions in Prostate Cancer of West african men and a Meta-Analysis of racial differences","volume":"186","author":"Zhou","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.jare.2025.10.026_b0630","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202420926","article-title":"Sprayed Aqueous Microdroplets for Spontaneous Synthesis of Functional Microgels","volume":"64","author":"Li","year":"2025","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"10.1016\/j.jare.2025.10.026_b0635","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5507\/bp.2014.065","article-title":"TMPRSS2-ERG gene fusion in prostate cancer","volume":"158","author":"Burdova","year":"2014","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"6","key":"10.1016\/j.jare.2025.10.026_b0640","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What is next generation sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"7","key":"10.1016\/j.jare.2025.10.026_b0645","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025791","article-title":"Next-Generation Sequencing strategies","volume":"9","author":"Levy","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jare.2025.10.026_b0650","doi-asserted-by":"crossref","first-page":"0673","DOI":"10.34133\/research.0673","article-title":"Isobutyrate confers resistance to inflammatory bowel disease through host-microbiota interactions in pigs","volume":"8","author":"Fang","year":"2025","journal-title":"Research"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0655","doi-asserted-by":"crossref","first-page":"e9380","DOI":"10.1097\/MD.0000000000009380","article-title":"Association of BRCA1\/2 mutations with ovarian cancer prognosis: an updated meta-analysis","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jare.2025.10.026_b0660","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/erm.2021.23","article-title":"Single-cell sequencing and its applications in bladder cancer","volume":"24","author":"Wei","year":"2022","journal-title":"Expert Rev Mol Med"},{"issue":"9","key":"10.1016\/j.jare.2025.10.026_b0665","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1245\/s10434-024-15725-8","article-title":"Recent advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0670","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment","volume":"35","author":"Zhou","year":"2017","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0675","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0680","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.drudis.2018.10.004","article-title":"Targeting VEGF-neuropilin interactions: a promising antitumor strategy","volume":"24","author":"Peng","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jare.2025.10.026_b0685","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.953555","article-title":"The emerging role of cancer nanotechnology in the panorama of sarcoma","volume":"10","author":"Mercatali","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0690","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020393","article-title":"The Impact of Nanomedicine on Soft Tissue Sarcoma Treated by Radiotherapy and\/or Hyperthermia: a Review","volume":"16","author":"Zachou","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.jare.2025.10.026_b0695","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1039\/D4NR03907F","article-title":"Engineered anti-HER2 drug delivery nanosystems for the treatment of breast cancer","volume":"17","author":"Vanni","year":"2025","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.jare.2025.10.026_b0700","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40364-024-00686-7","article-title":"New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology","volume":"12","author":"Feng","year":"2024","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.jare.2025.10.026_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020473","article-title":"Nano-Enabled strategies for the Treatment of Lung Cancer: potential Bottlenecks and Future Perspectives","volume":"11","author":"Alshammari","year":"2023","journal-title":"Biomedicines"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225008215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225008215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:51:24Z","timestamp":1782330684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225008215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":141,"alternative-id":["S2090123225008215"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.10.026","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}